Viatris Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
/ 
Frequently asked questions
To buy Viatris Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Viatris Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Viatris Inc. is VTRS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Viatris Inc. has its primary listing on NASDAQ. You can trade Viatris Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Viatris Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Viatris Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Viatris Inc..